| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Change in fair value of warrants issued | 2,747,460 | 1,062,818 | - | - |
| Total other income (expense), net | -2,755,056 | -1,516,243 | -24,417 | -17,062 |
| Net loss before provision for income tax expense | -5,047,902 | -4,031,803 | -1,998,281 | -2,104,860 |
| Provision for income tax expense | 3,182 | 28,984 | 2,559 | 5,419 |
| Net loss | -5,051,084 | -4,060,787 | -2,000,840 | -2,110,279 |
| Net loss per common share, basic | -4.74 | -0.17 | -0.16 | -0.19 |
| Net loss per common share, diluted | -4.74 | -0.17 | -0.16 | -0.19 |
| Weighted average common shares outstanding, basic | 1,066,350 | 24,021,546 | 12,391,867 | 11,389,308 |
| Weighted average common shares outstanding, diluted | 1,066,350 | 24,021,546 | 12,391,867 | 11,389,308 |
bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (BIAF)